Islet Cell Transplantation in Type 1 Diabetes: An Analysis of Efficacy Outcomes and Considerations for Trial Designs-Reference-Cited by-同舟云学术

Islet Cell Transplantation in Type 1 Diabetes: An Analysis of Efficacy Outcomes and Considerations for Trial Designs

Published:2012-04-05 Issue:7 Volume:12 Page:1898-1907
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:

Author:

Tiwari J. L.,Schneider B.,Barton F.,Anderson S. A.

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-6143.2012.04038.x/fullpdf

Reference8 articles.

1. U.S. Food and Drug Administration 2008 Guidance for Industry: Considerations for Allogenic Pancreatic Islet Cell Products http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm

2. Collaborative Islet Transplant Registry (CITR) http://www.citregistry.org

3. Analysis of survival by tumor response;Anderson;J Clin Oncol,1983

4. JMP Version 7.0 Software SAS Institute Inc.

5. Cytel Studio 8 Software CYTEL Software Corporation

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-arm phase 3 designs: An oxymoron?;Contemporary Clinical Trials;2024-06

2. Beta Cell Replacement Cellular Products: Emerging Regulatory Perspectives and Considerations for Program Development;Pluripotent Stem Cell Therapy for Diabetes;2023

3. Challenges, highlights, and opportunities in cellular transplantation: A white paper of the current landscape;American Journal of Transplantation;2021-07-22

4. Phase 3 trial of human islet‐after‐kidney transplantation in type 1 diabetes;American Journal of Transplantation;2020-08-09

5. Factors related to successful clinical islet isolation;Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas;2020